|
US5183884A
(en)
|
1989-12-01 |
1993-02-02 |
United States Of America |
Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
|
|
US6657103B1
(en)
|
1990-01-12 |
2003-12-02 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5344760A
(en)
|
1991-06-03 |
1994-09-06 |
Ciba Corning Diagnostics Corp. |
Method of cancer detection
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US6983227B1
(en)
|
1995-01-17 |
2006-01-03 |
Intertech Ventures, Ltd. |
Virtual models of complex systems
|
|
WO1997000271A1
(en)
|
1995-06-14 |
1997-01-03 |
The Regents Of The University Of California |
Novel high affinity human antibodies to tumor antigens
|
|
US5968511A
(en)
|
1996-03-27 |
1999-10-19 |
Genentech, Inc. |
ErbB3 antibodies
|
|
DK0896586T4
(en)
|
1996-03-27 |
2015-08-24 |
Genentech Inc |
ErbB3 antibodies.
|
|
ATE486937T1
(de)
|
1996-07-12 |
2010-11-15 |
Genentech Inc |
Chimärische heteromultimerische adhesine
|
|
US6255455B1
(en)
|
1996-10-11 |
2001-07-03 |
The Trustees Of The University Of Pennsylvania |
Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
|
|
US20020002276A1
(en)
|
1997-02-10 |
2002-01-03 |
Genentech, Inc. |
Chimeric heteromultimer adhesins
|
|
US6417168B1
(en)
|
1998-03-04 |
2002-07-09 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of treating tumors
|
|
GB2336695A
(en)
|
1998-04-20 |
1999-10-27 |
Teamware Group Oy |
Modelling a work process
|
|
AU4079999A
(en)
|
1998-05-15 |
1999-12-06 |
Imclone Systems Incorporated |
Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
|
|
AUPQ105799A0
(en)
|
1999-06-18 |
1999-07-08 |
Victor Chang Cardiac Research Institute, The |
Cell growth inhibition
|
|
US6949245B1
(en)
|
1999-06-25 |
2005-09-27 |
Genentech, Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
|
EP2110138A1
(en)
|
1999-08-27 |
2009-10-21 |
Genentech, Inc. |
Dosages for treatment of anti-erbB2 antibodies
|
|
US7390632B2
(en)
|
1999-09-30 |
2008-06-24 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 receptor isoforms
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
WO2001078652A2
(en)
|
2000-04-14 |
2001-10-25 |
Metabolon, Inc. |
Methods for drug discovery, disease treatment, and diagnosis using metabolomics
|
|
WO2001089566A1
(en)
|
2000-05-19 |
2001-11-29 |
Genentech, Inc. |
Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
|
|
US20020119148A1
(en)
|
2000-09-01 |
2002-08-29 |
Gerritsen Mary E. |
ErbB4 antagonists
|
|
US6871171B1
(en)
|
2000-10-19 |
2005-03-22 |
Optimata Ltd. |
System and methods for optimized drug delivery and progression of diseased and normal cells
|
|
EP1228766A1
(en)
|
2001-01-31 |
2002-08-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
PYK2 phosphorylation by HER3 induces tumor invasion
|
|
DK1392359T4
(da)
*
|
2001-05-11 |
2013-06-10 |
Ludwig Inst For Cancer Res Ltd |
Specifikke bindingsproteiner og deres anvendelser.
|
|
US7638302B2
(en)
|
2001-05-31 |
2009-12-29 |
Tumor Biology Investment Group, Inc. |
Soluble ErbB3 receptor isoforms
|
|
WO2003011897A1
(en)
|
2001-07-27 |
2003-02-13 |
The Regents Of The University Of California |
Modulation of heregulin and her3 interaction
|
|
WO2003014159A1
(en)
|
2001-08-03 |
2003-02-20 |
Commonwealth Scientific And Industrial Research Organisation |
Methods of screening based on the egf receptor crystal structure
|
|
AU2002326531A1
(en)
|
2001-08-03 |
2003-02-17 |
The Trustees Of The University Of Pennsylvania |
Monoclonal antibodies to activated erbb family members and methods of use thereof
|
|
EP1283053A1
(en)
|
2001-08-09 |
2003-02-12 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Inhibitors of HER3 activity
|
|
PL368458A1
(en)
|
2001-10-19 |
2005-03-21 |
Pharmamar S.A. |
Improved use of antitumoral compound in cancer therapy
|
|
US7415359B2
(en)
|
2001-11-02 |
2008-08-19 |
Gene Network Sciences, Inc. |
Methods and systems for the identification of components of mammalian biochemical networks as targets for therapeutic agents
|
|
CA2480099C
(en)
|
2002-03-26 |
2019-01-08 |
Zensun (Shanghai) Sci-Tech. Ltd. |
Erbb3 based methods and compositions for treating neoplasms
|
|
US20040248151A1
(en)
|
2002-04-05 |
2004-12-09 |
Ventana Medical Systems, Inc. |
Method for predicting the response to HER2-directed therapy
|
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US7332580B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The University Of California |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
|
US20040229380A1
(en)
|
2002-05-21 |
2004-11-18 |
Po-Ying Chan-Hui |
ErbB heterodimers as biomarkers
|
|
WO2004000102A2
(en)
|
2002-06-19 |
2003-12-31 |
Abgenix, Inc. |
Method for predicting response to epidermal growth factor receptor-directed therapy
|
|
CN1678634A
(zh)
|
2002-06-28 |
2005-10-05 |
多曼蒂斯有限公司 |
免疫球蛋白单个变体抗原结合区及其特异性构建体
|
|
WO2004053497A2
(en)
|
2002-12-11 |
2004-06-24 |
Ventana Medical Systems, Inc. |
Method for predicting the response to her2-directed therapy
|
|
BRPI0408928A
(pt)
|
2003-04-01 |
2006-09-12 |
Monogram Biosciences Inc |
métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente
|
|
CA2534898A1
(en)
|
2003-08-08 |
2005-02-17 |
Immunomedics, Inc. |
Bispecific antibodies for inducing apoptosis of tumor and diseased cells
|
|
EP1664716A4
(en)
|
2003-08-15 |
2008-08-13 |
Smithkline Beecham Corp |
CANCER BIOMARKERS
|
|
US8554486B2
(en)
|
2004-02-20 |
2013-10-08 |
The Mathworks, Inc. |
Method, computer program product, and apparatus for selective memory restoration of a simulation
|
|
EP2439284B1
(en)
|
2004-03-31 |
2019-05-08 |
The General Hospital Corporation |
Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
|
|
AU2005249396B2
(en)
|
2004-05-05 |
2011-10-20 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents for modulating biological activity
|
|
JP5422120B2
(ja)
|
2004-05-27 |
2014-02-19 |
ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト |
癌患者による上皮成長因子受容体阻害薬に対する臨床転帰の予測方法
|
|
US7794960B2
(en)
|
2004-06-04 |
2010-09-14 |
Glaxosmithkline Llc |
Predictive biomarkers in cancer therapy
|
|
CA2575791A1
(en)
|
2004-08-03 |
2006-02-16 |
Dyax Corp. |
Hk1-binding proteins
|
|
CN101061238B
(zh)
|
2004-08-06 |
2013-11-20 |
健泰科生物技术公司 |
使用生物标志的测定法和方法
|
|
JP2008532476A
(ja)
|
2004-08-12 |
2008-08-21 |
ダイアックス コーポレーション |
複合結合タンパク質
|
|
US20060136139A1
(en)
|
2004-10-12 |
2006-06-22 |
Elcock Adrian H |
Rapid computational identification of targets
|
|
WO2006044748A2
(en)
|
2004-10-15 |
2006-04-27 |
Monogram Biosciences, Inc. |
RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS
|
|
CA2587519A1
(en)
|
2004-12-07 |
2006-06-15 |
Genentech, Inc. |
Selecting patients for therapy with a her inhibitor
|
|
US7862995B2
(en)
|
2004-12-10 |
2011-01-04 |
Targeted Molecular Diagnostics |
Methods and materials for predicting responsiveness to treatment with dual tyrosine kinase inhibitor
|
|
CN101163501A
(zh)
|
2005-02-23 |
2008-04-16 |
梅里麦克制药股份有限公司 |
调节生物活性的双特异性结合剂
|
|
US20060204505A1
(en)
|
2005-03-08 |
2006-09-14 |
Sliwkowski Mark X |
Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
|
|
US20090061422A1
(en)
|
2005-04-19 |
2009-03-05 |
Linke Steven P |
Diagnostic markers of breast cancer treatment and progression and methods of use thereof
|
|
WO2007015935A2
(en)
|
2005-07-29 |
2007-02-08 |
Bayer Healthcare Llc |
Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
|
|
WO2007041502A2
(en)
|
2005-09-30 |
2007-04-12 |
Monogram Biosciences |
Methods for determining responsiveness to cancer therapy
|
|
CN101351563A
(zh)
|
2005-10-05 |
2009-01-21 |
阿斯利康(英国)有限公司 |
用于预测或监测病人对于ErbB受体药物的响应的方法
|
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
US7908091B2
(en)
|
2006-03-17 |
2011-03-15 |
Prometheus Laboratories Inc. |
Methods of predicting and monitoring tyrosine kinase inhibitor therapy
|
|
EP2049568A2
(en)
|
2006-04-07 |
2009-04-22 |
Københavns Universitet |
Erbb receptor-derived peptide fragments
|
|
US8367351B2
(en)
|
2006-05-05 |
2013-02-05 |
Historx, Inc. |
Methods for determining signal transduction activity in tumors
|
|
WO2008008500A2
(en)
|
2006-07-13 |
2008-01-17 |
Yale University |
Methods for making cancer prognoses based on the subcellular localization of biomarkers
|
|
JPWO2008032876A1
(ja)
*
|
2006-09-15 |
2010-01-28 |
学校法人東海大学 |
Ｅｒ陰性およびｈｅｒ２陰性である乳癌の予防または治療剤およびそのスクリーニング方法
|
|
EP2094870A4
(en)
|
2006-11-03 |
2010-05-05 |
Univ Texas |
BIFUNCTIONAL PREDICTORS OF SENSITIVITY AND RESISTANCE TO CANCER THERAPY
|
|
WO2008064884A1
(en)
|
2006-11-28 |
2008-06-05 |
U3 Pharma Gmbh |
Activated her3 as a marker for predicting therapeutic efficacy
|
|
US7825127B2
(en)
|
2006-12-28 |
2010-11-02 |
Takeda Pharmaceutical Company, Limited |
Method for treating cancer
|
|
NZ579644A
(en)
|
2007-02-16 |
2012-05-25 |
Merrimack Pharmaceuticals Inc |
Antibodies against erbb3 and uses thereof
|
|
MX2009008981A
(es)
|
2007-03-02 |
2009-09-02 |
Genentech Inc |
Prediccion de respuesta a un inhibidor her.
|
|
CA2683559C
(en)
|
2007-04-13 |
2019-09-24 |
Dana Farber Cancer Institute, Inc. |
Methods for treating cancer resistant to erbb therapeutics
|
|
AU2008250033A1
(en)
|
2007-05-11 |
2008-11-20 |
Enzon Pharmaceuticals, Inc. |
RNA antagonist compounds for the modulation of HER3
|
|
US20090054051A1
(en)
|
2007-08-22 |
2009-02-26 |
James Cavallo |
Attachable Headset for Portable Device
|
|
JP5639039B2
(ja)
|
2008-04-11 |
2014-12-10 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ヒト血清アルブミンリンカーおよびそのコンジュゲート
|
|
KR20110044905A
(ko)
*
|
2008-08-15 |
2011-05-02 |
메리맥 파마슈티컬즈, 인크. |
치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
|
|
CN102282168A
(zh)
|
2008-11-18 |
2011-12-14 |
梅里麦克制药股份有限公司 |
人血清白蛋白接头以及其结合物
|
|
AU2010284018C1
(en)
|
2009-08-21 |
2015-10-15 |
Merrimack Pharmaceuticals, Inc. |
Antibodies against the ectodomain of ErbB3 and uses thereof
|
|
JP2013507926A
(ja)
|
2009-10-14 |
2013-03-07 |
メリマック ファーマシューティカルズ インコーポレーティッド |
ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用
|
|
US8895001B2
(en)
|
2010-03-11 |
2014-11-25 |
Merrimack Pharmaceuticals, Inc. |
Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
|
|
WO2011139681A1
(en)
|
2010-04-26 |
2011-11-10 |
Merrimack Pharmaceuticals |
Assays for anti-drug antibodies in the presence of abundant endogenous protein counterpart of the drug
|
|
JP2013539453A
(ja)
|
2010-07-09 |
2013-10-24 |
エクセリクシス， インク． |
癌の治療のためのキナーゼ阻害物質の組み合わせ
|
|
FR2963868B1
(fr)
|
2010-08-11 |
2012-09-28 |
Valeo Systemes Thermiques |
Echangeur de chaleur comprenant un element chauffant serigraphie
|
|
AU2011341337A1
(en)
|
2010-12-10 |
2013-06-13 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of bispecific scFv conjugates
|
|
CA2828099A1
(en)
|
2011-02-24 |
2012-08-30 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-erbb3 agents
|
|
US20140134170A1
(en)
*
|
2011-03-11 |
2014-05-15 |
Merrimack Pharmaceuticals, Inc. |
Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
|
|
EP2815765A1
(en)
|
2011-03-15 |
2014-12-24 |
Merrimack Pharmaceuticals, Inc. |
Overcoming resistance to ERBB pathway inhibitors
|
|
MX336197B
(es)
|
2011-04-19 |
2016-01-11 |
Merrimack Pharmaceuticals Inc |
Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos.
|
|
CN103596592A
(zh)
|
2011-05-06 |
2014-02-19 |
梅里麦克制药股份有限公司 |
用于预防包含抗ErbB3试剂的联合治疗中的毒性药物间相互作用的方法
|
|
WO2012177440A1
(en)
|
2011-06-24 |
2012-12-27 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-erbb3 antibodies in combination with paclitaxel
|
|
MX2013015333A
(es)
|
2011-06-30 |
2014-07-09 |
Merrimack Pharmaceuticals Inc |
Anticuerpos anti-erbb3 en combinación con paclitaxel para el tratamiento de cánceres ginecológgicos.
|
|
AU2012294326A1
(en)
*
|
2011-08-10 |
2013-03-21 |
Merrimack Pharmaceuticals, Inc. |
Treatment of advanced solid tumors using combination of anti-ErbB3 immunotherapy and selected chemotherapy
|
|
CN104684579A
(zh)
|
2012-04-02 |
2015-06-03 |
梅里麦克制药股份有限公司 |
单特异性的和双特异性的抗-IGF-1R 和抗-ErbB3 抗体的剂量和施用
|
|
US9345766B2
(en)
|
2012-08-30 |
2016-05-24 |
Merrimack Pharmaceuticals, Inc. |
Combination therapies comprising anti-ERBB3 agents
|
|
WO2015100459A2
(en)
|
2013-12-27 |
2015-07-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
|
|
WO2015130554A2
(en)
|
2014-02-20 |
2015-09-03 |
Merrimack Pharmaceuticals, Inc. |
Dosage and administration of anti-igf-1r, anti-erbb3 bispecific antibodies, uses thereof and methods of treatment therewith
|